Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.Abla A. Creasey(California Institute for Regenerative Medicine), L. B. Hinshaw(Unknown)Journal of Clinical InvestigationJune 1, 199310.1172/jci116529Cited by 552SaveCiteExport RISWatch citationsRelated PapersEfficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis|JAMA|2003|958The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis|Critical Care Medicine|2001|68A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia|Critical Care|2009|45